

**AMENDMENT IN RESPONSE TO OFFICE ACTION**  
**United States Patent Application No. 09/889,530**

**REMARKS**

Applicant acknowledges with appreciation the statement in the Office Action that claims 15-17 are allowed. Applicant's undersigned representative thanks Examiner Krass for extending to her the courtesy of a telephone conference on April 1, 2005, during which he advised that the proposed amendments to the claims, as reflected herein, should place all the claims now currently pending in condition for allowance.

Claims 11 and 14 stands rejected under 35 U.S.C. § 102(b) as begin anticipated by Skibo et al. ("Studies of Pyrrolo[1,2- $\alpha$ ] benzimidazole quinine DT-Diapharose Substrate Activity...", *J. Med. Chem.*, Vol. 40, pp. 1327-1339 (1997). This rejection, although respectfully traversed, is believed to be moot in view of the amendments to the claims, and therefore withdrawal of this rejection is most respectfully requested.

Claims 18 and 21 stand rejected under 35 U.S.C. § 112, first paragraph, on the grounds that the specification allegedly does not enable the treatment of animal or human subjects afflicted with neoplastic disease. Although Applicant traverses this rejection on the grounds that there is sufficient support in the specification for one of skill in the art for methods for treatment of neoplastic disease in general, pursuant to the Applicant's representative's telephone conference with the Examiner, these claims have been amended to recite methods for treatment of cancer cells and tumors expressing elevated levels of DT-diaphorase. Support for these amendments can be found in various places throughout the specification, such as at page 2, third paragraph; page 3, lines 2-5; and page 6, lines 21-22.


**AMENDMENT IN RESPONSE TO OFFICE ACTION**  
**United States Patent Application No. 09/889,530**

In view of the foregoing, favorable consideration of the claims and allowance thereof is earnestly solicited. The Examiner is invited to telephone Applicant's undersigned representative if he believes that it would in any way facilitate prosecution of this application.

Dated: April 1, 2005

Respectfully submitted,

FENNEMORE CRAIG

  
Susan Stone Rosenfield

Reg. No. 36,287

3003 N. Central Avenue, Suite 2600

Phoenix, Arizona 85012-2913

Tel: (602) 916-5317

Fax (602) 916-5517